Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive. There are many reasons why the development of a potent and durable HIV-1 vaccine is challenging, including the extraordinary genetic diversity of HIV-1 and its complex mechanisms of immune evasion. HIV-1 envel...
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Sprache: | English |
| Veröffentlicht: |
Springer Nature
2022
|
| _version_ | 1826309721130270720 |
|---|---|
| author | Haynes, BF Wiehe, K Borrow, P Saunders, KO Korber, B Wagh, K McMichael, AJ Kelsoe, G Hahn, BH Alt, F Shaw, GM |
| author_facet | Haynes, BF Wiehe, K Borrow, P Saunders, KO Korber, B Wagh, K McMichael, AJ Kelsoe, G Hahn, BH Alt, F Shaw, GM |
| author_sort | Haynes, BF |
| collection | OXFORD |
| description | After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive. There are many reasons why the development of a potent and durable HIV-1 vaccine is challenging, including the extraordinary genetic diversity of HIV-1 and its complex mechanisms of immune evasion. HIV-1 envelope glycoproteins are poorly recognized by the immune system, which means that potent broadly neutralizing antibodies (bnAbs) are only infrequently induced in the setting of HIV-1 infection or through vaccination. Thus, the biology of HIV-1–host interactions necessitates novel strategies for vaccine development to be designed to activate and expand rare bnAb-producing B cell lineages and to select for the acquisition of critical improbable bnAb mutations. Here we discuss strategies for the induction of potent and broad HIV-1 bnAbs and outline the steps that may be necessary for ultimate success. |
| first_indexed | 2024-03-07T07:39:56Z |
| format | Journal article |
| id | oxford-uuid:ca7c7499-9cb9-4d9f-a74f-a8180d319f02 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:39:56Z |
| publishDate | 2022 |
| publisher | Springer Nature |
| record_format | dspace |
| spelling | oxford-uuid:ca7c7499-9cb9-4d9f-a74f-a8180d319f022023-04-14T11:13:55ZStrategies for HIV-1 vaccines that induce broadly neutralizing antibodiesJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ca7c7499-9cb9-4d9f-a74f-a8180d319f02EnglishSymplectic ElementsSpringer Nature2022Haynes, BFWiehe, KBorrow, PSaunders, KOKorber, BWagh, KMcMichael, AJKelsoe, GHahn, BHAlt, FShaw, GMAfter nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive. There are many reasons why the development of a potent and durable HIV-1 vaccine is challenging, including the extraordinary genetic diversity of HIV-1 and its complex mechanisms of immune evasion. HIV-1 envelope glycoproteins are poorly recognized by the immune system, which means that potent broadly neutralizing antibodies (bnAbs) are only infrequently induced in the setting of HIV-1 infection or through vaccination. Thus, the biology of HIV-1–host interactions necessitates novel strategies for vaccine development to be designed to activate and expand rare bnAb-producing B cell lineages and to select for the acquisition of critical improbable bnAb mutations. Here we discuss strategies for the induction of potent and broad HIV-1 bnAbs and outline the steps that may be necessary for ultimate success. |
| spellingShingle | Haynes, BF Wiehe, K Borrow, P Saunders, KO Korber, B Wagh, K McMichael, AJ Kelsoe, G Hahn, BH Alt, F Shaw, GM Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies |
| title | Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies |
| title_full | Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies |
| title_fullStr | Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies |
| title_full_unstemmed | Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies |
| title_short | Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies |
| title_sort | strategies for hiv 1 vaccines that induce broadly neutralizing antibodies |
| work_keys_str_mv | AT haynesbf strategiesforhiv1vaccinesthatinducebroadlyneutralizingantibodies AT wiehek strategiesforhiv1vaccinesthatinducebroadlyneutralizingantibodies AT borrowp strategiesforhiv1vaccinesthatinducebroadlyneutralizingantibodies AT saundersko strategiesforhiv1vaccinesthatinducebroadlyneutralizingantibodies AT korberb strategiesforhiv1vaccinesthatinducebroadlyneutralizingantibodies AT waghk strategiesforhiv1vaccinesthatinducebroadlyneutralizingantibodies AT mcmichaelaj strategiesforhiv1vaccinesthatinducebroadlyneutralizingantibodies AT kelsoeg strategiesforhiv1vaccinesthatinducebroadlyneutralizingantibodies AT hahnbh strategiesforhiv1vaccinesthatinducebroadlyneutralizingantibodies AT altf strategiesforhiv1vaccinesthatinducebroadlyneutralizingantibodies AT shawgm strategiesforhiv1vaccinesthatinducebroadlyneutralizingantibodies |